Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Habtemariam BA"'
Autor:
Hulton SA; Department of Nephrology, Birmingham Women's and Children's Hospital, Birmingham, UK., Groothoff JW; Department of Pediatric Nephrology, Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands., Frishberg Y; Division of Pediatric Nephrology, Shaare Zedek Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel., Koren MJ; Jacksonville Center for Clinical Research, Jacksonville, Florida, USA., Overcash JS; Velocity Clinical Research, San Diego, California, USA., Sellier-Leclerc AL; Hôpital Femme Mère Enfant and Centre d'Investigation Clinique Institut National de la Santé et de la Recherche Médicale, Hospices Civils de Lyon, ERKnet, Bron, France., Shasha-Lavsky H; Pediatric Nephrology Unit, Galilee Medical Center and Azrieli Faculty of Medicine, Bar-Ilan University, Nahariya, Israel., Saland JM; Icahn School of Medicine at Mount Sinai, New York, New York, USA., Hayes W; Department of Pediatric Nephrology, Great Ormond Street Hospital, London, UK., Magen D; Pediatric Nephrology Institute, Rambam Health Care Campus, Haifa, Israel., Moochhala SH; UCL Department of Renal Medicine, Royal Free Hospital, London, UK., Coenen M; Department of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, Bonn, Germany., Simkova E; Al Jalila Children's Hospital, Dubai, United Arabs Emirates., Garrelfs SF; Department of Pediatric Nephrology, Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands., Sas DJ; Division of Pediatric Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA., Meliambro KA; Icahn School of Medicine at Mount Sinai, New York, New York, USA., Ngo T; Alnylam Pharmaceuticals, Cambridge, Massachusetts, USA., Sweetser MT; Alnylam Pharmaceuticals, Cambridge, Massachusetts, USA., Habtemariam BA; Alnylam Pharmaceuticals, Cambridge, Massachusetts, USA., Gansner JM; Alnylam Pharmaceuticals, Cambridge, Massachusetts, USA., McGregor TL; Alnylam Pharmaceuticals, Cambridge, Massachusetts, USA., Lieske JC; Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA.
Publikováno v:
Kidney international reports [Kidney Int Rep] 2021 Dec 11; Vol. 7 (3), pp. 494-506. Date of Electronic Publication: 2021 Dec 11 (Print Publication: 2022).
Autor:
Frishberg Y; Division of Pediatric Nephrology, Shaare Zedek Medical Center, Jerusalem, Israel., Deschênes G; Department of Pediatric Nephrology, Hôpital Robert Debré, Paris, France., Groothoff JW; Department of Pediatric Nephrology, University of Amsterdam, Amsterdam, The Netherlands., Hulton SA; Department of Nephrology, Birmingham Women's and Children's Hospital, Birmingham, United Kingdom., Magen D; Pediatric Nephrology Institute, Ruth Children's Hospital, Haifa, Israel., Harambat J; Pediatric Nephrology Unit, Bordeaux University Hospital, Bordeaux, France., Van't Hoff WG; Department of Paediatric Nephrology, Great Ormond Street Hospital, London, United Kingdom., Lorch U; Richmond Pharmacology Ltd., London, United Kingdom., Milliner DS; Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota., Lieske JC; Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota., Haslett P; Alnylam Pharmaceuticals, Cambridge, Massachusetts., Garg PP; Alnylam Pharmaceuticals, Cambridge, Massachusetts., Vaishnaw AK; Alnylam Pharmaceuticals, Cambridge, Massachusetts., Talamudupula S; Alnylam Pharmaceuticals, Cambridge, Massachusetts., Lu J; Alnylam Pharmaceuticals, Cambridge, Massachusetts., Habtemariam BA; Alnylam Pharmaceuticals, Cambridge, Massachusetts., Erbe DV; Alnylam Pharmaceuticals, Cambridge, Massachusetts., McGregor TL; Alnylam Pharmaceuticals, Cambridge, Massachusetts., Cochat P; Center for Rare Renal Diseases and Institut National de la Santé et de la Recherche Médicale Pediatric Clinical Investigation Center, Hospices Civils de Lyon, Lyon, France.; Université de Lyon, Lyon, France.
Publikováno v:
Clinical journal of the American Society of Nephrology : CJASN [Clin J Am Soc Nephrol] 2021 Jul; Vol. 16 (7), pp. 1025-1036. Date of Electronic Publication: 2021 May 13.
Autor:
Habtemariam BA; Alnylam Pharmaceuticals, Cambridge, Massachusetts, USA., Karsten V; Alnylam Pharmaceuticals, Cambridge, Massachusetts, USA., Attarwala H; Moderna Therapeutics, Cambridge, Massachusetts, USA., Goel V; Alnylam Pharmaceuticals, Cambridge, Massachusetts, USA., Melch M; Alnylam Pharmaceuticals, Cambridge, Massachusetts, USA., Clausen VA; Alnylam Pharmaceuticals, Cambridge, Massachusetts, USA., Garg P; Alnylam Pharmaceuticals, Cambridge, Massachusetts, USA., Vaishnaw AK; Alnylam Pharmaceuticals, Cambridge, Massachusetts, USA., Sweetser MT; Alnylam Pharmaceuticals, Cambridge, Massachusetts, USA., Robbie GJ; Alnylam Pharmaceuticals, Cambridge, Massachusetts, USA., Vest J; Alnylam Pharmaceuticals, Cambridge, Massachusetts, USA.
Publikováno v:
Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2021 Feb; Vol. 109 (2), pp. 372-382. Date of Electronic Publication: 2020 Aug 13.
Autor:
Agarwal S; Alnylam Pharmaceuticals, Cambridge, MA, USA., Simon AR; Alnylam Pharmaceuticals, Cambridge, MA, USA., Goel V; Alnylam Pharmaceuticals, Cambridge, MA, USA., Habtemariam BA; Alnylam Pharmaceuticals, Cambridge, MA, USA., Clausen VA; Alnylam Pharmaceuticals, Cambridge, MA, USA., Kim JB; Alnylam Pharmaceuticals, Cambridge, MA, USA., Robbie GJ; Alnylam Pharmaceuticals, Cambridge, MA, USA.
Publikováno v:
Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2020 Jul; Vol. 108 (1), pp. 63-72. Date of Electronic Publication: 2020 Mar 07.
Autor:
Le RQ; Center for Biologics Evaluation and Research, Silver Spring, Maryland, USA., Li L; Center for Drug Evaluation and Research, Silver Spring, Maryland, USA., Yuan W; Center for Drug Evaluation and Research, Silver Spring, Maryland, USA., Shord SS; Center for Drug Evaluation and Research, Silver Spring, Maryland, USA., Nie L; Center for Drug Evaluation and Research, Silver Spring, Maryland, USA., Habtemariam BA; Center for Drug Evaluation and Research, Silver Spring, Maryland, USA., Przepiorka D; Center for Drug Evaluation and Research, Silver Spring, Maryland, USA Donna.Przepiorka@fda.hhs.gov., Farrell AT; Center for Drug Evaluation and Research, Silver Spring, Maryland, USA., Pazdur R; Center for Drug Evaluation and Research, Silver Spring, Maryland, USA.; Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
Publikováno v:
The oncologist [Oncologist] 2018 Aug; Vol. 23 (8), pp. 943-947. Date of Electronic Publication: 2018 Apr 05.
Autor:
Lee HZ; Office of Hematology and Oncology Products, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland. Hyon.Lee@fda.hhs.gov., Kwitkowski VE; Office of Hematology and Oncology Products, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland., Del Valle PL; Office of Hematology and Oncology Products, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland., Ricci MS; Office of Hematology and Oncology Products, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland., Saber H; Office of Hematology and Oncology Products, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland., Habtemariam BA; Office of Clinical Pharmacology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland., Bullock J; Office of Clinical Pharmacology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland., Bloomquist E; Office of Biostatistics, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland., Li Shen Y; Office of Biostatistics, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland., Chen XH; Office of New Drug Quality Assessment, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland., Brown J; Office of New Drug Quality Assessment, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland., Mehrotra N; Office of Clinical Pharmacology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland., Dorff S; Office of Clinical Pharmacology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland., Charlab R; Office of Clinical Pharmacology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland., Kane RC; Office of Hematology and Oncology Products, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland., Kaminskas E; Office of Hematology and Oncology Products, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland., Justice R; Office of Hematology and Oncology Products, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland., Farrell AT; Office of Hematology and Oncology Products, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland., Pazdur R; Office of Hematology and Oncology Products, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2015 Jun 15; Vol. 21 (12), pp. 2666-70. Date of Electronic Publication: 2015 Mar 23.